Retinal Vein Occlusion Treatment Market By Disease Type (Branch Retinal Vein Occlusion [BRVO], Central Retinal Vein Occlusion [CRVO], Hemiretinal Vein Occlusion [HRVO]); By Treatment Type (Anti-VEGF Therapy, Corticosteroid Therapy, Laser Therapy, Surgical and Other Treatments); By Drug (Aflibercept, Ranibizumab, Faricimab, Bevacizumab, Dexamethasone Implant, Other Drugs); By Route of Administration (Intravitreal Administration, Oral/Systemic Administration, Other Routes of Administration); By End User (Hospitals & Ophthalmology Clinics, Specialty Eye Centers, Ambulatory Surgical Centers, Other End Users); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Other Distribution Channels); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Retinal Vein Occlusion Treatment Market: Longer-Lasting Therapies Reshape Retinal Care – (Updated On: 3rd-Oct-2026)

The Global Retinal Vein Occlusion Treatment Market was valued at USD 3.05 billion in 2025 and is projected to reach around USD 5.01 billion by 2032, expanding at a CAGR of 7.35% during 2026–2032. RVO is the second-most common retinal vascular disease after diabetic retinopathy, with prevalence increasing sharply with age. Branch retinal vein occlusion (BRVO) accounts for the majority of cases, while central retinal vein occlusion (CRVO) represents a smaller but clinically significant patient group.

 

The United States has more than one million people affected by RVO, including approximately 870,000 with BRVO and 305,000 with CRVO. The large aging population and association of RVO with systemic vascular risk factors maintain a substantial pool of patients requiring ophthalmic monitoring and treatment.

 

Intravitreal anti-VEGF therapy remains the principal treatment for RVO-associated macular edema, with aflibercept, ranibizumab, faricimab, and off-label bevacizumab forming important treatment options. Steroid implants such as Ozurdex (dexamethasone) provide an alternative for selected patients, while laser photocoagulation retains a role in managing certain complications.

 

Competition is led by Regeneron/Bayer, Roche/Genentech, Novartis, and AbbVie, while biosimilars are increasing price competition in established anti-VEGF classes. Pipeline development is focused on longer treatment durability, alternative vascular and inflammatory targets, and new ocular drug-delivery approaches.

 

Through 2032, market growth will increasingly depend on expansion of the treated RVO population, longer-duration therapies, reduced injection burden, and improved control of macular edema, rather than prevalence growth alone.

 

Established Revenue Leaders and the Next Wave of RVO Treatment Growth

By Disease Type

Leading Subsegment – Branch Retinal Vein Occlusion (BRVO): 69.0% Share | USD 2.105 Billion in 2025 | 7.15% CAGR

BRVO represents the largest disease-specific revenue opportunity because it is considerably more prevalent than CRVO. Global epidemiological analysis estimated approximately 23.38 million BRVO cases among people aged 30–89 in 2015, compared with 4.67 million CRVO cases. BRVO prevalence was estimated at 0.64%, versus 0.13% for CRVO. The large treatable population, combined with macular edema requiring repeated ophthalmic treatment, supports BRVO's dominant contribution to anti-VEGF utilization.

Fastest-Growing Subsegment – Hemiretinal Vein Occlusion (HRVO): 5.0% Share | USD 0.153 Billion in 2025 | 8.10% CAGR

Hemiretinal Vein Occlusion (HRVO) accounted for approximately 5.0% of the Retinal Vein Occlusion Treatment Market, representing nearly USD 0.153 billion in 2025, and is projected to expand at an 8.10% CAGR through 2032. HRVO affects either the superior or inferior half of the retina and can cause macular edema and vision impairment. Treatment demand is supported by the growing use of anti-VEGF injections, including aflibercept, ranibizumab, and bevacizumab, alongside corticosteroids and laser photocoagulation for selected cases.

 

By Treatment Type

Leading and Fastest-Growing Subsegment– Anti-VEGF Therapy: 76.0% Share | USD 2.318 Billion in 2025 | 7.65% CAGR

Anti-VEGF therapy dominates the Retinal Vein Occlusion Treatment Market, accounting for an estimated 76.0% share and USD 2.318 billion in 2025, with the segment projected to expand at a 7.65% CAGR. Anti-VEGF agents remain the first-line treatment for RVO-associated macular edema by blocking vascular endothelial growth factor, which rises following retinal hypoxia. This mechanism reduces vascular leakage and macular swelling while limiting abnormal blood-vessel formation, supporting sustained clinical use and repeat treatment demand across RVO patients.

 

By Drug

Leading Subsegment – Aflibercept: 37.0% Share | USD 1.129 Billion in 2025 | 6.65% CAGR

Aflibercept accounted for an estimated 37.0% share of the Retinal Vein Occlusion Treatment Market, representing approximately USD 1.129 billion in 2025, and is projected to expand at a 6.65% CAGR. Aflibercept is widely used as a first-line or switch anti-VEGF therapy for macular edema associated with branch and central retinal vein occlusion. By binding VEGF-A and PlGF, it reduces retinal vascular leakage and edema, supporting visual improvement. Its durable activity also enables extended treatment intervals for suitable patients.

Fastest-Growing Subsegment – Faricimab: 16.0% Share | USD 0.488 Billion in 2025 | 14.25% CAGR

Faricimab accounted for an estimated 16.0% share of the Retinal Vein Occlusion Treatment Market, representing approximately USD 0.488 billion in 2025, and is projected to expand at a 14.25% CAGR through 2032. Market adoption is supported by Vabysmo’s dual-target mechanism, which inhibits both VEGF-A and Ang-2 to reduce retinal vascular leakage, inflammation, and macular edema associated with RVO. Its differentiated bispecific approach provides an additional treatment option for patients requiring intravitreal therapy and supports increasing commercial uptake within RVO treatment.

 

By Route of Administration

Leading & Fastest-Growing Subsegment – Intravitreal Administration: 94.0% Share | USD 2.867 Billion in 2025 | 7.45% CAGR

Intravitreal administration dominated the Retinal Vein Occlusion Treatment Market with a 94.0% share, representing approximately USD 2.867 billion in 2025, and is projected to expand at a 7.45% CAGR through 2032. Its dominance reflects the widespread use of direct intravitreal delivery for treating RVO-associated macular edema. Anti-VEGF therapies, including aflibercept, ranibizumab, bevacizumab, and faricimab, reduce retinal vascular leakage and swelling, while intravitreal corticosteroids provide an important treatment option for selected or insufficiently responsive patients.

 

By End User

Leading Subsegment – Hospitals & Ophthalmology Clinics: 67.0% Share | USD 2.044 Billion in 2025 | 7.25% CAGR

Hospitals & Ophthalmology Clinics accounted for an estimated 67.0% share of the Retinal Vein Occlusion Treatment Market, representing approximately USD 2.044 billion in 2025, and the segment is projected to expand at a 7.25% CAGR. Their leading position reflects the concentration of RVO diagnosis and treatment in specialized clinical settings, where ophthalmologists provide OCT and angiography-based assessment, anti-VEGF injections, steroid implants, laser photocoagulation, and surgical management of advanced complications. Hospitals also support coordinated management of vascular risk factors associated with RVO.

Fastest-Growing Subsegment – Specialty Eye Centers: 24.0% Share | USD 0.732 Billion in 2025 | 8.25% CAGR

Specialty eye centers accounted for 24.0% of the Retinal Vein Occlusion Treatment Market, representing approximately USD 0.732 billion in 2025, and are projected to expand at an 8.25% CAGR through 2032. Their strong market position reflects access to retinal specialists, advanced OCT and fluorescein angiography, and targeted treatments for CRVO and BRVO. These centers routinely administer anti-VEGF injections, including aflibercept and ranibizumab, alongside intravitreal steroids and laser photocoagulation, supporting recurring treatment demand and continued revenue growth.

 

By Distribution Channel

Leading Subsegment – Hospital Pharmacies: 63.0% Share | USD 1.922 Billion in 2025 | 7.20% CAGR

Hospital pharmacies are estimated to hold a 63.0% share of the Retinal Vein Occlusion Treatment Market, generating approximately USD 1.922 billion in 2025, and are projected to expand at a 7.20% CAGR during 2026–2032. Their leading position is supported by the hospital-based administration of intravitreal anti-VEGF therapies and corticosteroids. Hospital pharmacies manage procurement, sterile preparation, cold-chain storage, and dispensing of treatments such as aflibercept, ranibizumab, bevacizumab, and steroid implants, supporting reliable access to RVO therapies and coordinated ophthalmic care.

Fastest-Growing Subsegment – Specialty Pharmacies: 27.0% Share | USD 0.824 Billion in 2025 | 8.25% CAGR

Specialty pharmacies account for 27.0% of the Retinal Vein Occlusion Treatment Market, representing approximately USD 0.824 billion in 2025, and are projected to expand at a CAGR of 8.25% during 2026–2032. Their role is increasingly important as RVO treatment relies on high-cost anti-VEGF therapies and corticosteroids requiring coordinated access and handling. Specialty pharmacies support retina practices through prior authorization, financial assistance, temperature-controlled biologic distribution, inventory management, and patient adherence programs, helping patients maintain scheduled intravitreal treatment and reducing therapy interruptions.

 

By Geography

Leading Region – North America: 42.0% Share | USD 1.281 Billion in 2025 | 6.95% CAGR

North America led the Retinal Vein Occlusion Treatment Market with a 42.0% share, valued at approximately USD 1.281 billion in 2025, and is projected to expand at a 6.95% CAGR. Regional demand is supported by established ophthalmology networks and widespread use of intravitreal anti-VEGF therapy for RVO-associated macular edema. Eylea (aflibercept), Lucentis (ranibizumab), Vabysmo (faricimab), and off-label Avastin (bevacizumab) remain important treatment options, while expanding biosimilar availability is broadening access and increasing competition in retinal care.

Fastest-Growing Region – Asia-Pacific: 24.0% Share | USD 0.732 Billion in 2025 | 9.15% CAGR

Asia-Pacific accounted for 24.0% of the Retinal Vein Occlusion Treatment Market, representing approximately USD 0.732 billion in 2025, and is projected to expand at a 9.15% CAGR. Growth is supported by rising retinal disease diagnosis, expanding access to ophthalmology services, and wider use of anti-VEGF therapies for RVO-associated macular edema. Increasing adoption of treat-and-extend and as-needed dosing protocols is also helping reduce treatment burden while supporting sustained therapeutic uptake across major Asia-Pacific healthcare markets.

 

Durability and Dual-Pathway Innovation Raise the Competitive Stakes

Regeneron Pharmaceuticals / Bayer – Aflibercept Franchise Anchors RVO Treatment

Regeneron Pharmaceuticals, together with Bayer, holds a major commercial position in retinal vascular therapy through the Eylea (aflibercept) franchise. Aflibercept is established for treating macular edema following retinal vein occlusion, placing the companies directly within the largest treatment segment—anti-VEGF therapy. Regeneron reported USD 4.4 billion in combined U.S. net sales for Eylea HD and Eylea during 2025, demonstrating the commercial scale of the broader aflibercept ophthalmology franchise, although these sales cover multiple retinal indications rather than RVO alone. Importantly, Eylea HD received FDA approval for macular edema following RVO in 2025, extending the franchise into higher-dose treatment for this patient population.

Roche / Genentech – Vabysmo Drives the Next Wave of Anti-VEGF Competition

Roche, through Genentech in the United States, has strengthened its RVO position with Vabysmo (faricimab), a bispecific antibody targeting both VEGF-A and Ang-2. Vabysmo is approved for macular edema following RVO and is increasingly important in the competitive shift toward therapies designed around improved disease control and treatment durability. Global Vabysmo sales reached CHF 4.102 billion in 2025, increasing 12% at constant exchange rates, with U.S. sales alone reaching CHF 2.857 billion. These figures include nAMD, DME, and RVO rather than RVO alone, but demonstrate the rapid commercial penetration of the franchise. Roche identified Vabysmo among its major growth drivers in 2025, with particularly strong growth internationally.

Other Key Companies and Their Role in the RVO Treatment Market

• AbbVie — Provides Ozurdex (dexamethasone intravitreal implant 0.7 mg), an important non-anti-VEGF option specifically indicated for macular edema following BRVO or CRVO.

• Santen Pharmaceutical — Supports aflibercept commercialization in Japan and announced the February 2026 launch of an aflibercept 40 mg/mL intravitreal injection kit covering macular edema secondary to RVO among its four indications.

• Kodiak Sciences — Developing tarcocimab tedromer/Zenkuda as a longer-duration retinal biologic; its 568-patient Phase III BEACON RVO trial demonstrated non-inferiority with dosing every eight weeks versus aflibercept every four weeks at six months. Approximately half of tarcocimab-treated patients received no injections during the second six months.

• Kodiak Sciences — Is also developing KSI-501, an investigational bispecific biologic designed to inhibit both VEGF and IL-6, potentially expanding RVO treatment beyond conventional VEGF-only targetin.

• Annexin Pharmaceuticals — Represents an emerging non-VEGF competitor through ANXV, an investigational recombinant annexin A5 therapy being clinically studied in patients with recently diagnosed RVO.

 

Analyst Commentary: Longer-Lasting Therapies Open New Paths in RVO Care

The retinal vein occlusion treatment market is moving beyond frequent, conventional VEGF suppression toward longer-lasting and more biologically differentiated retinal therapies. The strongest commercial opportunities are emerging around extended-durability anti-VEGF agents, dual-pathway biologics targeting VEGF and complementary vascular mechanisms, higher-dose formulations, and novel non-VEGF approaches.

 

Retinal Vein Occlusion Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.05 Billion
Revenue Forecast in 2032	USD 5.01 Billion
Overall Growth Rate	CAGR of 7.35% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Type, By Drug, By Route of Administration, By End User, By Distribution Channel, By Geography
By Disease Type	Branch Retinal Vein Occlusion (BRVO), Central Retinal Vein Occlusion (CRVO), Hemiretinal Vein Occlusion (HRVO)
By Treatment Type	Anti-VEGF Therapy, Corticosteroid Therapy, Laser Therapy, Surgical and Other Treatments
By Drug	Aflibercept, Ranibizumab, Faricimab, Bevacizumab, Dexamethasone Implant, Other Drugs
By Route of Administration	Intravitreal Administration, Oral/Systemic Administration, Other Routes of Administration
By End User	Hospitals & Ophthalmology Clinics, Specialty Eye Centers, Ambulatory Surgical Centers, Other End Users
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Other Distribution Channels
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Aging population and rising RVO prevalence, increasing adoption of intravitreal anti-VEGF therapies, growing demand for longer-duration retinal treatments, efforts to reduce injection burden, improved management of macular edema, and expanding availability of biosimilar anti-VEGF therapies
Customization Option	Available upon request